The EU has approved the tablet formulation of Calquence for patients suffering from chronic lymphocytic leukaemia Read more
Eterna Therapeutics and Lineage Cell Therapeutics Partner to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications Read more
Beckley Psytech’s BPL-003, a synthetic formulation of 5-MeO-DMT (Mebufotenin), granted FDA Investigational New Drug (IND) approval for Phase IIb clinical trial Read more
Vaxcyte’s VAX-24 IND Cleared by FDA for Prevention of Invasive Pneumococcal Disease in Infants Read more
FDA Accepts Alnylam’s Supplemental NDA for ONPATTRO (patisiran) to Treat Cardiomyopathy in ATTR Amyloidosis Read more
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review Read more
UK Grants Full Marketing Authorization to Karyopharm and Menarini Group’s NEXPOVIO for Multiple Myeloma Treatment Read more
FDA has granted fast track designation to Biohaven’s Taldefgrobep Alfa for the treatment of spinal muscular atrophy Read more